Overview

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to estimate the efficacy of MEGF0444A treatment to disease progression, combined with oxaliplatin + folinic acid + 5-Fluorouracil (mFOLFOX-6) + bevacizumab therapy in participants with metastatic colorectal cancer (CRC).

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Bevacizumab
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin